Gleevec is the trade name, generic name of imatinib mesylate tablets, for small intestinal mesenchymal tumors after surgery for patients generally need to take about 6 to 18 months, but for mesenchymal tumors are relatively large in size, the operation can not be removed radically, then need to take long-term. Some research statistics show that within 5 years after surgery for gastrointestinal mesenchymal tumors, 66% of patients who took Gleevec for 3 years did not experience tumor recurrence; while 48% of patients who took Gleevec for only 1 year after surgery did not experience tumor recurrence. Imatinib mesylate tablets are mainly used in the treatment of leukemia, malignant gastric mesenchymal stromal tumors, eosinophilia and other diseases, in order to minimize the chances of metastasis and recurrence, it is recommended that patients take imatinib mesylate tablets for at least 6 to 18 months after surgery. However, for patients whose mesenchymal tumors are relatively large in size and cannot be removed radically during surgery, they need to take it for a long period of time, which can effectively inhibit the mesenchymal tumor cells in the gastrointestinal tract and prevent them from spreading. Patients who have undergone surgery for small intestinal mesenchymal tumor need to take imatinib mesylate tablets under the guidance of a doctor, do not treat with medication privately, and undergo regular review.